MSD assay development: a practical guide for drug discovery teams
Electrochemiluminescence-based detection is increasingly used in early drug discovery, where low sample volume, low-abundance targets, or complex biology make colorimetric readouts difficult. MSD assay development uses Meso Scale Discovery technology to measure proteins, cytokines, antibodies, pathway signals, and pharmacodynamic endpoints with high sensitivity and broad quantitative range. Compared with traditional ELISA formats, MSD assays often provide lower background, wider range, and better performance in matrices such as serum, plasma, cell lysate, and conditioned media. Multiplexing adds another practical advantage. Several analytes can be measured in one well, reducing sample demand and preserving biological context across target engagement and translational biomarker studies. Assay value depends on more than signal intensity. Format selection, reagent quality, matrix assessment, and controls determine whether the method becomes a dependable project tool.
Why MSD technology matters in drug discovery
Traditional ELISA remains useful, but it can struggle when analyte is scarce or matrix effects dominate the readout. Meso Scale Discovery addresses many of these constraints through electrochemiluminescence detection on carbon electrode plates. Capture reagents bind analyte, ruthenium-labelled detection antibodies complete the complex, and electrical stimulation triggers measurable light.
What is MSD technology and how does ECL detection work?
MSD technology turns target binding into a light signal you can measure. In a typical MSD immunoassay, capture reagents are placed on carbon electrode plates. After antigen binding, a ruthenium-labelled detection antibody forms the sandwich complex. Electrical stimulation at the electrode surface excites the ruthenium tag through an electrochemical reaction. The reader records light and converts signal intensity into concentration.
This chemistry gives the meso scale discovery assay format clear advantages over colorimetric ELISA. Signal generation occurs close to the electrode surface, limiting background from unbound reagent and matrix components. The result is often stronger signal-to-noise performance, for dilute biomarkers or weak pathway responses.
Compared with fluorescent detection, an electrochemiluminescence assay is less affected by autofluorescence from serum, plasma, cell lysate, tissue homogenate, or test compounds. The wider dynamic range also reduces repeated dilution. For drug discovery studies, these features support quantification across screening, target engagement, translational biomarker, immunogenicity, and safety pharmacology workflows.
When to choose MSD over ELISA or other immunoassay formats
MSD works well for low-abundance analytes, particularly when sample volume is limited and low-end precision is critical. Typical examples include cytokines, phosphorylated pathway markers, soluble receptors, and pharmacodynamic biomarkers. The electrochemiluminescent readout can deliver stronger signal-to-noise performance than standard colorimetric ELISA when background limits sensitivity.
Multiplex requirements are another decision point. If several analytes need measurement from the same sample, MSD can preserve material, reduce plate burden, and keep related biology in one analytical run. This matters in pathway profiling, inflammation panels, dose-response experiments, and translational biomarker studies.
Complex matrices are a good reason to choose MSD. Serum, plasma, cell lysate, conditioned media, and tissue homogenates can introduce interference, nonspecific binding, or autofluorescence. A well-optimised custom MSD assay can often manage these issues more effectively than Standard ELISA. High throughput screening may also favour MSD when broad dynamic range, automation compatibility, and fewer repeat dilutions improve workflow efficiency. ELISA remains sufficient for many single-analyte assays with abundant targets, clean matrices, modest sensitivity needs, and established reagent pairs. Format selection should follow biology, matrix, throughput, and decision risk. See ‘Choosing the right assay for drug discovery‘.
Key steps in MSD assay development: from format selection to validation
MSD assay development should begin with the research question, not the plate layout. Pharmacodynamic, screening, and translational biomarker assays can share a platform, but require different performance priorities.
Define target and analyte
Target biology, analyte form, expected concentration range, and sample matrix should be defined early. Total protein, phosphorylated protein, free ligand, bound ligand, cytokine, antibody, or complexed biomarker can each require a different capture strategy. Species cross-reactivity, endogenous baseline, treatment-induced change, and available sample volume also shape design.
Antibody pair selection and testing
Antibody screening should compare multiple capture and detection pairings under matched matrix conditions. Affinity alone is not enough. Epitope compatibility, nonspecific binding, lot consistency, cross-reactivity, and performance after ruthenium labelling all matter. Orthogonal confirmation is useful when isoforms, cleavage products, or related family members may interfere.
Plate format choice
Standard MSD plates are suitable when validated capture reagents or established panels match the study question. Custom plates become useful when the assay requires a specific capture antibody, novel analyte combination, altered spot layout, or matrix-specific optimisation. Cell-based workflows require linked planning around stimulation, lysis, and endpoint readout.
Spike-and-recovery and parallelism testing
Matrix effects should be tested before final optimisation. Spike-and-recovery measures whether known analyte additions can be recovered accurately in serum, plasma, lysate, conditioned media, or tissue homogenate. Parallelism checks whether diluted endogenous samples track the standard curve. Poor recovery or nonparallel dilution often signals interference, binding protein effects, hook risk, or calibrator mismatch.
Sensitivity, linearity, and quantification
Analytical characterisation should establish limit of detection, lower limit of quantification, upper limit of quantification, linearity, and usable dynamic range. LLOQ should reflect acceptable precision and accuracy, not only statistical separation from blank signal. Dilutional linearity helps define the working range for real samples.
Validation per fit-for-purpose guidelines
Drug discovery validation is usually fit for purpose, not GMP. Precision, accuracy, selectivity, stability, dilution tolerance, robustness, and inter-run performance should match assay role and project risk.
Common challenges in MSD assay development and how to solve them
Matrix interference usually shows up early. Serum, plasma, tissue homogenate, and cell lysate can carry binding proteins, heterophilic antibodies, lipids, proteases, or soluble receptors. Any of these can distort recovery. Spike-and-recovery should be run early, with neat and diluted matrix compared against buffer standards. Parallelism then checks whether the endogenous signal tracks like the calibrator. If it does not, the fix may be matrix-matched standards, a different diluent, stronger blocker screening, sample dilution, protease inhibition, or a change in capture or detection antibody concentration.
Then there is the high-dose hook effect. Excess analyte can saturate both capture and detection reagents. Sandwich formation drops, and the signal can look falsely low. This is most likely with abundant targets, concentrated dosing studies, or poorly defined sample ranges. Serial dilution of high-signal samples is the first check. Broader dilution schemes, more reagent capacity, and predefined dilution rules help prevent the wrong call.
Lots can change. Reagents, antibodies, calibrators, blockers, plates. New lots should go through bridging against qualified reference material before project samples are tested. Acceptance criteria should include curve shape, EC50, LLOQ, ULOQ, recovery, and quality control performance at low, mid, and high concentrations.
Multiplexing brings its own set of problems. Cross-reactivity, signal bleed, and analyte competition can all make the biology look cleaner or noisier than it really is. Pairwise testing, singleplex-to-multiplex comparison, spot-specific controls, and antigen excess experiments help identify incompatible pairs before the full panel is used. More discussion of avoidable assay risks is covered in our blog ‘Common pitfalls in assay development and how to avoid them‘.
MSD assay development at Discovery Studio
Discovery Studio’s approach to MSD assay development is built around the biological decision the assay must support. Custom assay development can include antibody pair screening, plate format selection, matrix optimisation, sensitivity profiling, and fit-for-purpose validation. Multiplexed biomarker panels are designed with attention to analyte compatibility, cross-reactivity risk, sample volume constraints, and interpretability across pharmacodynamic or translational readouts. MSD workflows can also be integrated with in vitro biology programmes, including an MSD cell-based assay, pathway modulation experiments, compound profiling, and biomarker response analysis. The aim is to generate data that remains analytically sound and useful for project decisions. For project-specific discussions, get in touch with us.
Search all newsposts
Popular Posts
Tags
Get in touch with us
Frequently asked questions about MSD assay development
How long does MSD assay development typically take?
Typical development takes four to eight weeks, depending on reagent readiness, matrix complexity, and validation depth. Novel targets or multiplex formats may require longer optimisation.
How do I validate an MSD assay for use in a drug development programme?
Validation should be fit for purpose. MSD assay development usually assesses precision, accuracy, sensitivity, selectivity, stability, dilution tolerance, and inter-run robustness.
When should a custom MSD assay be considered?
A custom format is useful when commercial kits do not match the target biology, matrix, species, or performance range. It is also valuable for novel biomarker panels.
Can MSD assays be multiplexed, and what is a practical upper limit?
Several analytes can sit on the same MSD run through multiplexed multi-spot plates. The real limit is usually antibody compatibility, analyte abundance, matrix effects, and cross-reactivity, not the number of spots printed on the plate.
What sample types are compatible with MSD?
What samples work? Most of the usual discovery matrices. People use serum, plasma, cell lysate, conditioned media, tissue homogenate, and cerebrospinal fluid. But recovery, dilutional linearity, and interference still need to be checked.
What is the difference between MSD and standard sandwich ELISA?
A standard sandwich ELISA relies on colorimetric or fluorescent detection. MSD uses electrochemiluminescence, so the readout is light from the electrode surface, with better signal-to-noise, sensitivity, and dynamic range in many assays.
Is MSD suitable for cell-based assays or only analyte quantification?
Cell-based assays are also a good fit. MSD can read phosphorylated protein, pathway activation, cytokine release, and pharmacodynamic biomarkers, along with soluble analytes.
References
- Maximizing Synergies Between Venture Studios and Life Science Companies. Assessed from https://blog.victech.com/maximizing-synergies-between-venture-studios-and-life-science-companies.
- Biotech Venture Studios: Revolutionising Innovation in Life Sciences. Assessed from https://www.efbpublic.org/biotech-venture-studios/.
- Moiana, D., Del Prete, T., Franchi, L., Ghezzi, A., & Rangone, A. (2025, September). What Drives Venture Studios Success? Uncovering Successful Configurations in the European Landscape. In European Conference on Innovation and Entrepreneurship(pp. 464-472). Academic Conferences International Limited.
- Coelsch-Foisner, C., Vandeweghe, L., & Clarysse, B. (2024). Understanding A New Player in The Entrepreneurial Ecosystem: The Venture Studio. Available at SSRN 4757394.
- Kohler, T. (2016). Corporate accelerators: Building bridges between corporations and startups. Business horizons, 59(3), 347-357.
- Belingheri, P., & Lechner, C. (2025). The Venture Building Phenomenon. In Venture Builders and the Creation of Scaleups: De-Risking Entrepreneurship to Drive High-Growth Companies (pp. 29-55). Cham: Springer Nature Switzerland.
- Weiblen, T., & Chesbrough, H. W. (2015). Engaging with startups to enhance corporate innovation. California management review, 57(2), 66-90.
- Moiana, D., Ghezzi, A., & Rangone, A. (2025). Venture studios beyond the hype: Key challenges and a way forward. Business Horizons.
- Moiana, D., Ghezzi, A., & Rangone, A. (2024, September). Venture Studios: Beyond Entrepreneurial Support Organisations? A Case Study Analysis and Framework. In European Conference on Innovation and Entrepreneurship(pp. 532-539). Academic Conferences International Limited.
- Startup Incubator vs. Venture Studio: What’s the Difference? Assessed from https://www.highalpha.com/blog/startup-incubator-vs-venture-studio-whats-the-difference.